Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

OKYO Pharma Ltd Director's Dealing 2022

May 16, 2022

34361_dirs_2022-05-16_891f9375-665f-41ad-b0c1-fd8511c7a7c3.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: OKYO Pharma Ltd (OKYO)
CIK: 0001849296
Period of Report: 2022-05-16

Reporting Person: BRANCACCIO JOHN P (Director)

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Option (right to buy) $0.2025 2028-08-19 Ordinary Shares (450000) Direct
Option (right to buy) $0.0640 2031-08-31 Ordinary Shares (900000) Direct
Option (right to buy) $0.1045 2032-01-31 Ordinary Shares (100000) Direct

Footnotes

F1: 25% will vest each year on June 10 beginning on August 20, 2020.

F2: 25% will vest each year on June 10 beginning on August 31, 2021.

F3: Vests in equal amounts over 3 years beginning on January 31, 2022.